Literature DB >> 17401788

Psychotropic drugs for terminally ill patients with respiratory disease.

Kouji Kanemoto1, Hiroaki Satoh, Katsunori Kagohashi, Koichi Kurishima, Hiroichi Ishikawa, Morio Ohtsuka.   

Abstract

Utilization of psychotropic drugs including hypnotics, sedatives, and parenteral morphine for terminally ill patients with respiratory disease has not been reported precisely. To better understand these drugs for dying patients with respiratory disease, we focused on the last month of life of them. A chart review, which was focused on symptoms and managements, in the last month of life of 337 patients who died of respiratory disease between April 2000 and March 2005 were performed. Hypnotics were prescribed in 35.8% and 23.2% of patients with malignant and non-malignant disease, respectively. Sedatives such as haloperidol and midazolam were utilized in 34.4% of patients with malignant disease, and 30.4% of those with non-malignant disease. Sixty-seven percent of patients with malignant and 22.4% of those with non-malignant disease had parenteral morphine. In patients with malignant disease, three of the main reasons for administration of morphine were pain, dyspnea, or terminal restlessness. In all of the patients with non-malignant disease, however, parenteral morphine was prescribed for the treatment of dyspnea. Our results showed that psychotropic drugs and parenteral morphine are required in some of terminally ill patients with respiratory disease. Although careful individualization of medication is appropriate, guideline for the prescribing psychotropic drugs for these patients will be required.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401788

Source DB:  PubMed          Journal:  Tuberk Toraks        ISSN: 0494-1373


  1 in total

1.  Psychiatric comorbidity among terminally ill patients in general practice in the Netherlands: a comparison between patients with cancer and heart failure.

Authors:  Chong Guan Ng; Ellen Dijkstra; Hugo Smeets; Marco P M Boks; Niek J de Wit
Journal:  Br J Gen Pract       Date:  2013-01       Impact factor: 5.386

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.